Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study

[1]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[2]  J. Baeten,et al.  Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. , 2015, AIDS.

[3]  L. van Damme,et al.  The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills , 2015, Journal of acquired immune deficiency syndromes.

[4]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[5]  Megha L Mehrotra,et al.  Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study , 2014, Journal of acquired immune deficiency syndromes.

[6]  Megha L Mehrotra,et al.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.

[7]  Kimberly A. Koester,et al.  Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection , 2014, Journal of acquired immune deficiency syndromes.

[8]  K. Amico,et al.  Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  W. Heneine,et al.  Preexposure prophylaxis for the prevention of HIV infection – 2014 : a clinical practice guideline , 2014 .

[10]  P. Polgreen,et al.  Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Grohskopf,et al.  Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States , 2013, Journal of acquired immune deficiency syndromes.

[12]  S. Hosek,et al.  The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men , 2013, Journal of acquired immune deficiency syndromes.

[13]  I. Wilson,et al.  Provider Guidance for Linking Patients to Antiretroviral Therapy Adherence Interventions , 2013, Journal of the International Association of Providers of AIDS Care.

[14]  K. Amico,et al.  Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness , 2012, Current opinion in HIV and AIDS.

[15]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[16]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[17]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[18]  James D. Scott,et al.  Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel , 2012, Annals of Internal Medicine.

[19]  R. Grant,et al.  Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment , 2012, AIDS and Behavior.

[20]  C. Bova,et al.  A Proposal for Quality Standards for Measuring Medication Adherence in Research , 2012, AIDS and Behavior.

[21]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[22]  I. Wilson,et al.  Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence , 2007, AIDS and Behavior.